Celgene exercises option, pays $100mm up front, plus earn-outs, for Quanticel
Executive Summary
Three-and-a-half years after paying $45mm for an undisclosed stake in the company, Celgene Corp. has exercised its option to buy privately held Quanticel Pharmaceuticals Inc. outright for $100mm up front. The deal also includes up to $385mm in earn-outs based on R&D and regulatory progress.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice